What is claimed is:

1. A method to treat, prevent or ameliorate neurodegenerative conditions comprising administering to a subject in need thereof an effective amount of a modulator of a protein selected from the group consisting of those disclosed in Table 3 or 3A.

2. The method of Claim 1, wherein said condition is Alzheimer's Disease (AD).

3. The method of Claim 1, wherein said modulator inhibits the biochemical function of said protein in said subject.

4. The method of Claim 3, wherein said modulator comprises one or more antibodies to said protein, or fragments thereof, wherein said antibodies or fragments thereof can inhibit the biochemical function of said protein in said subject.

5. The method of Claim 1, wherein said modulator enhances the biochemical function of said protein in said subject.

6. The method of Claim 1, wherein said modulator inhibits gene expression of said protein in said subject.

7. The method of Claim 6, wherein said modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple-helix DNA, ribozymes, RNA aptamers, siRNA, double- and single-stranded RNA, wherein said substances are designed to inhibit gene expression of said protein.

8. The method of Claim 1, wherein said modulator enhances the gene expression of said protein in said subject.

9. A method to treat, prevent or ameliorate neurodegenerative conditions comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a modulator of a protein selected from the group consisting of those disclosed in Table 3 or 3A.

10. The method of Claim 9, wherein said condition is AD.

11. The method of Claim 9, wherein said modulator inhibits the biochemical function of said protein in said subject.

12. The method of Claim 11, wherein said modulator comprises one or more antibodies to said protein, or fragments thereof, wherein said antibodies or fragments thereof can inhibit the biochemical function of said protein.

13. The method of Claim 9, wherein said modulator enhances the biochemical function of said protein in said subject.

14. The method of Claim 9, wherein said modulator inhibits gene expression of said protein in said subject.

15. The method of Claim 14, wherein said modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple-helix DNA, ribozymes, RNA aptamers, siRNA, double- and single-stranded RNA, wherein said substances are designed to inhibit gene expression of said protein.

16. The method of Claim 9, wherein said modulator enhances gene expression of said protein in said subject.

17. A method to identify modulators useful to treat, prevent or ameliorate neurodegenerative conditions comprising assaying for the ability of a candidate modulator to modulate the biochemical function of a protein selected from the group consisting of those disclosed in Table 3 or 3A.

18. The method of Claim 17, wherein said method further comprises assaying for the ability of an identified modulator to reverse the pathological effects observed *in vitro* or *in vivo* models of said conditions.

19. The method of Claim 17, wherein said method further comprises assaying for the ability of an identified modulator to reverse the pathological effects observed in clinical studies with subjects with said conditions.

20. The method according to Claim 17, wherein said condition is AD.

21. A method to identify modulators useful to treat, prevent or ameliorate neurodegenerative conditions comprising assaying for the ability of a candidate modulator to modulate gene expression of a protein selected from the group consisting of those disclosed in Table 3 or 3A.

22. The method according to Claim 21, wherein said method further comprises assaying for the ability of an identified inhibitory modulator to reverse the pathological effects observed *in vitro* or *in vivo* models of said condition.

23. The method according to Claim 21, wherein said method further comprises assaying for the ability of an identified inhibitory modulator to reverse the pathological effects observed in clinical studies with subjects with said condition.

24. The method according to Claim 21, wherein said condition is AD.

25. A pharmaceutical composition comprising a modulator to a protein selected from the group consisting of those disclosed in Table 3 or 3A in an amount effective to treat, prevent or ameliorate neurodegenerative conditions in a subject in need thereof.

26. The pharmaceutical composition according to Claim 25, wherein said condition is AD.

27. The pharmaceutical composition according to Claim 25, wherein said modulator inhibits the biochemical function of said protein.

28. The pharmaceutical composition of Claim 25, wherein said modulator comprises one or more antibodies to said protein, or fragments thereof, wherein said antibodies or fragments thereof can inhibit the biochemical function of said protein.

29. The pharmaceutical composition according to Claim 25, wherein said modulator enhances the biochemical function of said protein.

30. The pharmaceutical composition according to Claim 25, wherein said modulator inhibits gene expression of said protein.

31. The pharmaceutical composition of Claim 30, wherein said modulator comprises any one or more substances selected from the group consisting of antisense oligonucleotides, triple-helix DNA, ribozymes, RNA aptamer, siRNA, double- and single-stranded RNA, wherein said substances are designed to inhibit gene expression of said protein.

32. The pharmaceutical composition according to Claim 25, wherein said modulator enhances gene expression of said protein.

33. A method to diagnose subjects suffering from neurodegenerative conditions who may be suitable candidates for treatment with modulators to a protein selected from the group consisting of those disclosed in Table 3 or 3A, comprising assaying mRNA levels of any one or more of said proteins in a biological sample from said subject wherein subjects with altered levels compared to controls would be suitable candidates for modulator treatment.

34. A method to diagnose subjects suffering from neurodegenerative conditions who may be suitable candidates for treatment with modulators to a protein selected from the group consisting of those disclosed in Table 3 or 3A, comprising detecting levels of any one or more of said proteins in a biological sample from said subject wherein subjects with altered levels compared to controls would be suitable candidates for modulator treatment.

35. A method to treat, prevent or ameliorate a neurodegenerative comprising:

(a) assaying for mRNA levels of a protein selected from the group consisting of those disclosed in Table 3 or 3A in a subject; and

(b) administering to a subject with altered levels of mRNA of said protein compared to controls a modulator to said protein in an amount sufficient to treat, prevent or ameliorate the pathological effects of said condition.

36. The method of Claim 35, wherein said condition is AD.

37. The method of Claim 35, wherein said modulator enhances the gene expression of said protein.

38. The method of Claim 35, wherein said modulator inhibits the gene expression of said protein.

39. A method to treat, prevent or ameliorate a neurodegenerative condition comprising:

(a) assaying for levels of a protein selected from the group consisting of those disclosed in Table 3 or 3A in a subject; and

(b) administering to a subject with altered levels of said protein compared to controls a modulator to said protein in an amount sufficient to treat, prevent or ameliorate the pathological effects of said condition.

40. The method of Claim 39, wherein said condition is AD.

41. The method of Claim 39, wherein said modulator enhances the biochemical function of said protein.

42. The method of Claim 39, wherein said modulator inhibits the biochemical function of said protein.

43. A diagnostic kit for detecting mRNA levels of a protein selected from the group consisting of those disclosed in Table 3 or 3A in a biological sample, said kit comprising:

(a) a polynucleotide of a polypeptide set forth in Table 3 or 3A or a fragment thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of Table 3 or 3A of the present invention encoded by the polynucleotide of (a);

(d) an antibody to the polypeptide of (c);

(e) an RNAi sequence complementary to that of (a),

wherein components (a), (b), (c), (d) or (e) may comprise a substantial component.

44. A diagnostic kit for detecting levels of a protein selected from the group consisting of those disclosed in Table 3 or 3A in a biological sample, said kit comprising:

(a) a polynucleotide of a polypeptide set forth in Table 3 or 3A or a fragment thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of Table 3 or 3A of the present invention encoded by the polynucleotide of (a);

(d) an antibody to the polypeptide of (c);

(e) an RNAi sequence complementary to that of (a),

wherein components (a), (b), (c), (d) or (e) may comprise a substantial component.